Clinical Trials Logo
  1. Home
  2. Cardiac Sarcoidosis
  3. NCT05954507

Evaluation of the Prognostic Value of PET/MRI in Cardiac Sarcoidosis — SARCASTIM  

Cardiac Sarcoidosis Clinical Trial

Official title:
Prospective Comparative Multicenter Study Evaluating the Prognostic Interest of PET/MRI in Cardiac Sarcoidosis

Clinical Trial Summary

Cardiac damage is the second leading cause of death in patients with sarcoidosis, after lung damage. Today's challenge is to diagnose the disease as effectively as possible, and to develop tools for better risk stratification, especially for sudden death, in order to better target therapies and implantable devices, such as corticoids and immunosuppressant. The hypothesis is that combined PET (Positron Emission Tomography)/MRI (Magnetic Resonance Imaging) could be a relevant prognostic marker of progression, and would significantly improve diagnostic performance in patients with suspected cardiac sarcoidosis (CS). This study will also make it possible to distinguish sequellar fibrosis lesions from granulomatous lesions and assess the therapeutic response. Incorporating PET/MRI into the diagnostic strategy for patients with suspected CS could therefore improve their management.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05954507
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact Vania TACHER, PHD
Phone 01 49 81 29 29
Email vania.tacher@aphp.fr
Status Not yet recruiting
Phase N/A
Start date May 1, 2024
Completion date May 1, 2029
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04017936 - Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis Phase 2
Recruiting NCT06131112 - Macrophage PET/CT Imaging Using 64Cu-DOTATATE for the Diagnosis of Cardiac Sarcoidosis
Terminated NCT03923049 - Feasibility and Accuracy of Hybrid Magnetic Resonance and Positron Emission Tomography With 18F-Fluorodeoxyglucose in Diagnosing Cardiac Sarcoidosis N/A
Recruiting NCT04737317 - Diagnostic Criteria in Cardiac Sarcoidosis
Recruiting NCT03057002 - UTSW HP [13-C] Pyruvate Injection in HCM
Completed NCT03599414 - CASPA: CArdiac Sarcoidosis in PApworth
Withdrawn NCT02812849 - Somatostatin Receptor Imaging in Cardiac Sarcoidosis
Completed NCT01729169 - Cardiac Sarcoidosis: FDG PET vs. Ga-DOTANOC PET N/A
Completed NCT03549598 - d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis Phase 4
Recruiting NCT04758650 - Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis Phase 2
Recruiting NCT04206163 - Somatostatin Receptor Imaging in Acute Myocarditis and Cardiac Sarcoidosis N/A
Recruiting NCT05499637 - [68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation Phase 2
Recruiting NCT03593759 - Cardiac Sarcoidosis Randomized Trial Phase 3
Recruiting NCT05145023 - Development and Validation of a Health-related Quality of Life Tool for Patients With Cardiac Sarcoidosis
Recruiting NCT03705884 - PET/MR Imaging In Patients With Cardiac Sarcoidosis N/A
Enrolling by invitation NCT04774549 - Inflammatory Cardiomyopathy Bern Registry
Recruiting NCT03049254 - Mayo AVC Registry and Biobank
Completed NCT03746847 - PET Imaging in Patients With Suspected Cardiac Sarcoidosis
Recruiting NCT01477359 - Cardiac Sarcoidosis Multi-Center Prospective Cohort
Terminated NCT03103490 - 18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation Phase 2